TickerFacts.

Avalo Therapeutics, Inc. (AVTX): Cost of Revenue

Annual figures by period end, from SEC filings.

Older than the company's other figures. The latest Cost of Revenue is for the year ended 2023-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report this line under the concept TickerFacts maps.

$1.28M
Year ended 2023-12-31
+62.4%
3-year compound annual growth
-17.0%
5-year compound annual growth
$3.43M2015-12-31: $02016-12-31: $02017-12-31: $635.6K2018-12-31: $3.26M2019-12-31: -$566.5K2020-12-31: $300.0K2021-12-31: $1.49M2022-12-31: $3.43M2023-12-31: $1.28M$1.28M
2015-12-31 Cost of Revenue (USD) 2023-12-31
Period endedCost of RevenueChange YoYSource filing
2023-12-31$1.28M-62.6%2024-03-29, From 2023-01-01
2022-12-31$3.43M+130.3%2024-03-29, From 2022-01-01
2021-12-31$1.49M+397.0%2023-03-29, From 2021-01-01
2020-12-31$300.0Kn/m2022-03-02, From 2020-01-01
2019-12-31-$566.5Kn/m2020-03-11, From 2019-01-01
2018-12-31$3.26M+413.0%2020-03-11, From 2018-01-01
2017-12-31$635.6Kn/a2019-03-18, From 2017-01-01
2016-12-31$0n/a2018-04-02, From 2016-01-01
2015-12-31$0n/a2018-04-02, From 2015-01-01